2Bursa Medical Park Hastanesi, Beyin ve Sinir Cerrahisi Bölümü, Bursa, Türkiye
3Başkent Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Adana, Türkiye
4Başkent Üniversitesi, Tıp Fakültesi, Medikal Onkoloji Anabilim Dalı, Adana, Türkiye
5Başkent Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Adana, Türkiye
6Başkent Üniversitesi, Tıp Fakültesi, Radyoloji Anabilim Dalı, Adana, Türkiye AIM: To analyze the efficacy of treatment protocols in patients with newly diagnosed glioblastoma (GBM) following the first surgery at the Department of Neurosurgery, Adana Teaching and Medical Research Center, Baskent University Faculty of Medicine.
MATERIAL and METHODS: A total of 80 patients who were treated with a diagnosis of GBM between January 2004 and December 2013 were analyzed retrospectively. The median survival time of the 68 patients who died were calculated and prognostic factors affecting survival were determined following univariate and multivariate statistical analysis.
RESULTS: Median survival time of the patients who died was detected as 7.09 ± 0.83 months. 1 and 2-year survival rates were 80.9% and 19.1%, respectively. Post-treatment tumor recurrence was observed in 8 patients and they were reoperated. According to univariate analysis, age (p<0.01), preoperative Karnofsky Performance Scale (KPS) score ≥70 (p<0.0001), postoperative KPS score ≥70 (p<0.0001), type of surgical resection (p<0.0001), reoperation (p<0.0001), adjuvant radiotherapy (RT) (p<0.0001), concurrent Temozolomide with RT protocol (p<0.0001) and adding antiangiogenic combination therapy of Bevacizumab and Irinotecan to pthe atients with recurrence of tumor (p<0.0001) were found to be positive prognostic factors.
CONCLUSION: Age, preoperative and postoperative KPS equal or greater than 70, re-operation and concurrent Temozolomide with the RT protocol were identified as independent prognostic factors for prolonged survival rate.
Anahtar Kelimeler : Bevacizumab, Glioblastoma, Irinotecan, Radiotherapy, Temozolomide